RGNX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -241.28% compared to Regenxbio's net margin of 23.56%. Regenxbio's return on equity of -70.45% beat Gilead Sciences's return on equity of 2.5%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 427.6%. On the other hand Gilead Sciences has an analysts' consensus of $112.50 which suggests that it could grow by 7.27%. Given that Regenxbio has higher upside potential than Gilead Sciences, analysts believe Regenxbio is more attractive than Gilead Sciences.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.96% to investors and pays a quarterly dividend of $0.79 per share. Regenxbio pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Regenxbio's net income of -$51.2M is lower than Gilead Sciences's net income of $1.8B. Notably, Regenxbio's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 283.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.66x versus 4.59x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -241.28% compared to Regenxbio's net margin of -225.53%. Regenxbio's return on equity of -70.45% beat Insmed's return on equity of -41989.34%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 427.6%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 36.44%. Given that Regenxbio has higher upside potential than Insmed, analysts believe Regenxbio is more attractive than Insmed.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Insmed quarterly revenues of $104.4M. Regenxbio's net income of -$51.2M is higher than Insmed's net income of -$235.5M. Notably, Regenxbio's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.66x versus 31.65x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -241.28% compared to Regenxbio's net margin of 7.87%. Regenxbio's return on equity of -70.45% beat Merit Medical Systems's return on equity of 9.36%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 427.6%. On the other hand Merit Medical Systems has an analysts' consensus of $117.82 which suggests that it could grow by 30.09%. Given that Regenxbio has higher upside potential than Merit Medical Systems, analysts believe Regenxbio is more attractive than Merit Medical Systems.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.356%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Merit Medical Systems quarterly revenues of $355.2M. Regenxbio's net income of -$51.2M is lower than Merit Medical Systems's net income of $27.9M. Notably, Regenxbio's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 44.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.66x versus 3.96x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -241.28% compared to Regenxbio's net margin of 24.16%. Regenxbio's return on equity of -70.45% beat Sarepta Therapeutics's return on equity of 20.83%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 427.6%. On the other hand Sarepta Therapeutics has an analysts' consensus of $155.00 which suggests that it could grow by 187.35%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Regenxbio's net income of -$51.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 23.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.66x versus 3.16x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.